Sorbitol

Sorbitol

SCHEMBL2418929

C=CC.C=CC.OCCO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TDP1 Q9NUW8 2/20 0.55
KDM4E B2RXH2 2/20 0.46
PDE4A P27815 1/20 0.41
USP2 O75604 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
TOP1 P11387 1/20 0.37
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mannitol SCHEMBL22575783 1.00 LMNA (0.58) LMNAL3MBTL1TDP1KDM4EPDE4A
Mannitol SCHEMBL28092438 0.95 LMNA (0.65) LMNAL3MBTL1TDP1KDM4EPDE4A
Mannitol SCHEMBL27743384 0.92 LMNA (0.61) LMNAL3MBTL1TDP1KDM4EPDE4A
E968 SCHEMBL14793512 0.89 LMNA (0.40) LMNAL3MBTL1TDP1KDM4E
Xylitol SCHEMBL9070177 0.89 LMNA (0.56) LMNAL3MBTL1TDP1KDM4EPDE4A
Mannitol SCHEMBL20640359 0.87 LMNA (0.55) LMNAL3MBTL1TDP1KDM4EPDE4A
Sorbitol SCHEMBL1220679 0.83 LMNA (0.50) LMNAL3MBTL1TDP1KDM4EPDE4A
Sorbitol SCHEMBL7769394 0.83 LMNA (0.50) LMNAL3MBTL1TDP1KDM4EPDE4A
Sorbitol SCHEMBL11254388 0.83 LMNA (0.85) LMNAL3MBTL1TDP1KDM4EPDE4A
Mannitol SCHEMBL21081888 0.83 LMNA (0.85) LMNAL3MBTL1TDP1KDM4EPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3989916-A1 OIL-IN- WATER EMULSION GEL COMPOSITION L V M H RECHERCHE (FR) 2022-05-04 EP disclosed
WO-2021048577-A1 OIL-IN- WATER EMULSION GEL COMPOSITION L V M H RECHERCHE (FR) 2021-03-18 WO disclosed
US-20200199689-A1 Method for Predicting Effectiveness of Angiogenesis Inhibitor EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-06-25 US disclosed
EP-1862301-B1 Image recording material, planographic printing plate precursor, and planographic printing method using the same FUJIFILM CORP (JP) 2011-09-28 EP disclosed
US-20070298351-A1 IMAGE RECORDING MATERIAL, PLANOGRAPHIC PRINTING PLATE PRECURSOR, AND PLANOGRAPHIC PRINTING METHOD USING THE SAME FUJIFILM CORPORATION (JP) 2007-12-27 US disclosed
EP-1862301-A1 Image recording material, planographic printing plate precursor, and planographic printing method using the same FUJIFILM Corporation (JP) 2007-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199689-A1 Method for Predicting Effectiveness of Angiogenesis Inhibitor VEGFA, BRAF, FLT4 LMNA 4287/4885L3MBTL1 1840/4885TDP1 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.